Inozyme Pharma Inc (INZY) - Total Liabilities
Based on the latest financial reports, Inozyme Pharma Inc (INZY) has total liabilities worth $63.37 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Inozyme Pharma Inc (INZY) investment intensity to see how much of total assets are deployed in long-term investments.
Inozyme Pharma Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Inozyme Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see INZY total asset value.
Inozyme Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Inozyme Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Perimeter Acquisition Corp. I Class A Ordinary Shares
NASDAQ:PMTR
|
USA | $9.30 Million |
|
Cipher Pharmaceuticals Inc
TO:CPH
|
Canada | CA$19.60 Million |
|
Genesyslogic
TWO:6104
|
Taiwan | NT$1.74 Billion |
|
Ginwa Enterprise Group Inc
SHG:600080
|
China | CN¥370.80 Million |
|
GemVax&KAEL Co.Ltd
KQ:082270
|
Korea | ₩101.65 Billion |
|
Enel Generacion Costanera SA
BA:CECO2
|
Argentina | AR$102.36 Billion |
|
Namchow Chemical Industrial Co Ltd
TW:1702
|
Taiwan | NT$17.91 Billion |
|
BRT Realty Trust
NYSE:BRT
|
USA | $529.25 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Inozyme Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See INZY equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.99 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Inozyme Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Inozyme Pharma Inc (2018–2024)
The table below shows the annual total liabilities of Inozyme Pharma Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $65.36 Million | +8.26% |
| 2023-12-31 | $60.37 Million | +190.22% |
| 2022-12-31 | $20.80 Million | +45.74% |
| 2021-12-31 | $14.27 Million | +26.76% |
| 2020-12-31 | $11.26 Million | -86.13% |
| 2019-12-31 | $81.16 Million | +41.35% |
| 2018-12-31 | $57.42 Million | -- |
About Inozyme Pharma Inc
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney… Read more